Glycans and glycoproteins as specific biomarkers for cancer

[1]  L. R. Ruhaak,et al.  Protein-Specific Differential Glycosylation of Immunoglobulins in Serum of Ovarian Cancer Patients. , 2016, Journal of proteome research.

[2]  L. R. Ruhaak,et al.  Serum Glycans as Risk Markers for Non–Small Cell Lung Cancer , 2016, Cancer Prevention Research.

[3]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[4]  L. R. Ruhaak,et al.  A Method for Comprehensive Glycosite-Mapping and Direct Quantitation of Serum Glycoproteins. , 2015, Journal of proteome research.

[5]  A. Motsinger-Reif,et al.  Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. , 2015, Journal of proteome research.

[6]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[7]  C. Lebrilla,et al.  A Method for In-Depth Structural Annotation of Human Serum Glycans That Yields Biological Variations. , 2015, Analytical chemistry.

[8]  W. Hancock,et al.  Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. , 2015, Journal of proteome research.

[9]  Albert Sickmann,et al.  Current strategies and findings in clinically relevant post-translational modification-specific proteomics , 2015, Expert review of proteomics.

[10]  Michelle A. Anderson,et al.  Large-scale identification of core-fucosylated glycopeptide sites in pancreatic cancer serum using mass spectrometry. , 2015, Journal of proteome research.

[11]  David M. Rocke,et al.  The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. , 2015, EuPA open proteomics.

[12]  J. Koomen,et al.  Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease. , 2015, Journal of proteomics.

[13]  Y. Rombouts,et al.  Glycosylation characteristics of colorectal cancer. , 2015, Advances in cancer research.

[14]  K. Abbott,et al.  Functional impact of tumor-specific N-linked glycan changes in breast and ovarian cancers. , 2015, Advances in cancer research.

[15]  J. Nyalwidhe,et al.  Altered glycosylation in prostate cancer. , 2015, Advances in cancer research.

[16]  C. Lebrilla,et al.  Applications of Multiple Reaction Monitoring to Clinical Glycomics , 2015, Chromatographia.

[17]  Daniel Kolarich,et al.  Clinical Glycomics Employing Graphitized Carbon Liquid Chromatography–Mass Spectrometry , 2014, Chromatographia.

[18]  Benjamin A. Neely,et al.  MALDI Imaging Mass Spectrometry Profiling of N-Glycans in Formalin-Fixed Paraffin Embedded Clinical Tissue Blocks and Tissue Microarrays , 2014, PloS one.

[19]  N. Leymarie,et al.  Confident Assignment of Site-Specific Glycosylation in Complex Glycoproteins in a Single Step , 2014, Journal of proteome research.

[20]  B. Ma,et al.  GlycoMaster DB: software to assist the automated identification of N-linked glycopeptides by tandem mass spectrometry. , 2014, Journal of proteome research.

[21]  V. Adam,et al.  MALDI-TOF MS as evolving cancer diagnostic tool: a review. , 2014, Journal of pharmaceutical and biomedical analysis.

[22]  Ziding Feng,et al.  Mass-Selected Site-Specific Core-Fucosylation of Ceruloplasmin in Alcohol-Related Hepatocellular Carcinoma , 2014, Journal of proteome research.

[23]  Zhikai Zhu,et al.  Absolute Quantitation of Glycosylation Site Occupancy Using Isotopically Labeled Standards and LC-MS , 2014, Journal of The American Society for Mass Spectrometry.

[24]  Jodie L. Abrahams,et al.  Cell surface protein glycosylation in cancer , 2014, Proteomics.

[25]  Mack T. Ruffin,et al.  Glycoprotein Biomarker Panel for Pancreatic Cancer Discovered by Quantitative Proteomics Analysis , 2014, Journal of proteome research.

[26]  Haixu Tang,et al.  Computational framework for identification of intact glycopeptides in complex samples. , 2014, Analytical chemistry.

[27]  L Renee Ruhaak,et al.  Oligosaccharide analysis by mass spectrometry: a review of recent developments. , 2014, Analytical chemistry.

[28]  Michelle A. Anderson,et al.  Label‐free relative quantification of alpha‐2‐macroglobulin site‐specific core‐fucosylation in pancreatic cancer by LC‐MS/MS , 2013, Electrophoresis.

[29]  Ronald A Miller,et al.  Mass spectrometry-based biomarkers in drug development. , 2014, Advances in experimental medicine and biology.

[30]  H. Verheul,et al.  Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[31]  Haojie Lu,et al.  Mass spectrometry-based N-glycoproteomics for cancer biomarker discovery , 2014, Clinical Proteomics.

[32]  Q. Shan,et al.  Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. , 2013, Biochemical and biophysical research communications.

[33]  K. Ueda.  Glycoproteomic strategies: From discovery to clinical application of cancer carbohydrate biomarkers , 2013, Proteomics. Clinical applications.

[34]  C. Lebrilla,et al.  Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. , 2013, Analytical chemistry.

[35]  T. Wen,et al.  Glycoproteomic analysis of tissues from patients with colon cancer using lectin microarrays and nanoLC-MS/MS. , 2013, Molecular bioSystems.

[36]  Serenus Hua,et al.  Automated assignments of N- and O-site specific glycosylation with extensive glycan heterogeneity of glycoprotein mixtures. , 2013, Analytical chemistry.

[37]  Heather Desaire,et al.  Software for automated interpretation of mass spectrometry data from glycans and glycopeptides. , 2013, The Analyst.

[38]  K. Makambi,et al.  Quantitative Liquid Chromatography-Mass Spectrometry-Multiple Reaction Monitoring (LC-MS-MRM) Analysis of Site-specific Glycoforms of Haptoglobin in Liver Disease* , 2013, Molecular & Cellular Proteomics.

[39]  L. R. Ruhaak,et al.  Developments in the Identification of Glycan Biomarkers for the Detection of Cancer , 2013, Molecular & Cellular Proteomics.

[40]  Yong J. Kil,et al.  Byonic: Advanced Peptide and Protein Identification Software , 2012, Current protocols in bioinformatics.

[41]  Y. Mechref,et al.  Quantification of glycopeptides by multiple reaction monitoring liquid chromatography/tandem mass spectrometry. , 2012, Rapid communications in mass spectrometry : RCM.

[42]  Pauline M Rudd,et al.  Glycans as cancer biomarkers. , 2012, Biochimica et biophysica acta.

[43]  R. Buckanovich,et al.  Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. , 2012, Journal of proteome research.

[44]  Scott R. Kronewitter,et al.  The glycolyzer: Automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery , 2012, Proteomics.

[45]  P. Massion,et al.  The State of Molecular Biomarkers for the Early Detection of Lung Cancer , 2012, Cancer Prevention Research.

[46]  R. Aebersold,et al.  Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.

[47]  L. McDonnell,et al.  N-glycosylation of Colorectal Cancer Tissues , 2012, Molecular & Cellular Proteomics.

[48]  W. Alley,et al.  N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. , 2012, Journal of proteome research.

[49]  C. Lebrilla,et al.  Application of nano-LC-based glycomics towards biomarker discovery. , 2011, Bioanalysis.

[50]  C. Lebrilla,et al.  Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. , 2011, The Analyst.

[51]  Haixu Tang,et al.  Improving confidence in detection and characterization of protein N-glycosylation sites and microheterogeneity. , 2011, Rapid communications in mass spectrometry : RCM.

[52]  Angela M Zivkovic,et al.  Simultaneous and extensive site-specific N- and O-glycosylation analysis in protein mixtures. , 2011, Journal of proteome research.

[53]  Yue Fan,et al.  Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. , 2011, Glycobiology.

[54]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[55]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[56]  T. Conrads,et al.  Advances in proximal fluid proteomics for disease biomarker discovery. , 2010, Journal of proteome research.

[57]  Scott R. Kronewitter,et al.  High-Mannose Glycans are Elevated during Breast Cancer Progression* , 2010, Molecular & Cellular Proteomics.

[58]  Pauline M Rudd,et al.  Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. , 2010, Analytical chemistry.

[59]  R. Linhardt,et al.  Proteoglycomics: recent progress and future challenges. , 2010, Omics : a journal of integrative biology.

[60]  Yehia Mechref,et al.  Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. , 2010, Analytical chemistry.

[61]  S. Dalton,et al.  Glycoproteomic analysis of embryonic stem cells: identification of potential glycobiomarkers using lectin affinity chromatography of glycopeptides. , 2010, Journal of proteome research.

[62]  Leonor David,et al.  Alterations in glycosylation as biomarkers for cancer detection , 2010, Journal of Clinical Pathology.

[63]  Susan J Fisher,et al.  Sweetening the pot: adding glycosylation to the biomarker discovery equation. , 2010, Clinical chemistry.

[64]  Yusuke Nakamura,et al.  Development of Serum Glycoproteomic Profiling Technique; Simultaneous Identification of Glycosylation Sites and Site-Specific Quantification of Glycan Structure Changes* , 2010, Molecular & Cellular Proteomics.

[65]  C. Lebrilla,et al.  A glycomics approach to the discovery of potential cancer biomarkers. , 2010, Methods in molecular biology.

[66]  Scott R. Kronewitter,et al.  Glycomics and disease markers. , 2009, Current opinion in chemical biology.

[67]  R. Nagler.  Saliva as a tool for oral cancer diagnosis and prognosis. , 2009, Oral oncology.

[68]  Hyun Joo An,et al.  Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. , 2009, Current opinion in chemical biology.

[69]  Ji Yeon Lee,et al.  Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. , 2009, Journal of proteome research.

[70]  William J. Griffiths,et al.  Mass spectrometry: from proteomics to metabolomics and lipidomics. , 2009, Chemical Society reviews.

[71]  K. Killeen,et al.  Profile of native N‐linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time‐of‐flight mass spectrometry , 2009, Proteomics.

[72]  André M Deelder,et al.  Oligosaccharide analysis by graphitized carbon liquid chromatography–mass spectrometry , 2009, Analytical and bioanalytical chemistry.

[73]  A. Kuno,et al.  Focused Differential Glycan Analysis with the Platform Antibody-assisted Lectin Profiling for Glycan-related Biomarker Verification*S , 2009, Molecular & Cellular Proteomics.

[74]  Magnus Palmblad,et al.  Mass spectrometry in clinical proteomics – from the present to the future , 2008, Proteomics. Clinical applications.

[75]  A. Varki,et al.  Glycosylation Changes in Cancer , 2009 .

[76]  M. Bissell.  A First-Generation Multiplex Biomarker Analysis of Urine For The Early Detection of Prostate Cancer , 2009 .

[77]  Carlito B. Lebrilla,et al.  The prospects of glycan biomarkers for the diagnosis of diseases. , 2009, Molecular bioSystems.

[78]  J. Hirabayashi,et al.  Enrichment strategies for glycopeptides. , 2009, Methods in molecular biology.

[79]  Scott R. Kronewitter,et al.  Glycomic Approach for Potential Biomarkers on Prostate Cancer: Profiling of N-Linked Glycans in Human Sera and pRNS Cell Lines , 2009, Disease markers.

[80]  László Drahos,et al.  GlycoMiner: a new software tool to elucidate glycopeptide composition. , 2008, Rapid communications in mass spectrometry : RCM.

[81]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[82]  Joseph Zaia,et al.  Mass spectrometry and the emerging field of glycomics. , 2008, Chemistry & biology.

[83]  M. Nakano,et al.  Fucosylated haptoglobin is a novel marker for pancreatic cancer: Detailed analyses of oligosaccharide structures , 2008, Proteomics.

[84]  Yehia Mechref,et al.  Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. , 2008, Clinical chemistry.

[85]  Sudhir Bahadur,et al.  Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry*S , 2008, Molecular & Cellular Proteomics.

[86]  H. Desaire,et al.  Glycopeptide analysis by mass spectrometry. , 2008, The Analyst.

[87]  S. Hanash,et al.  Mining the plasma proteome for cancer biomarkers , 2008, Nature.

[88]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[89]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[90]  K. Aoki,et al.  Targeted glycoproteomic identification of biomarkers for human breast carcinoma. , 2008, Journal of proteome research.

[91]  Yehia Mechref,et al.  Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. , 2008, Journal of proteome research.

[92]  T. Nakagawa,et al.  Biological function of fucosylation in cancer biology. , 2007, Journal of biochemistry.

[93]  Irina Kusmartseva,et al.  Panel of serum biomarkers for the diagnosis of lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Pauline M Rudd,et al.  Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. , 2007, Glycobiology.

[95]  Elise C. Kohn,et al.  Proteomics as a Tool for Biomarker Discovery , 2007, Disease markers.

[96]  N. Kelleher,et al.  Decoding protein modifications using top-down mass spectrometry , 2007, Nature Methods.

[97]  André M Deelder,et al.  Glycoproteomics based on tandem mass spectrometry of glycopeptides. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[98]  Y. Mechref,et al.  Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.

[99]  Naoyuki Taniguchi,et al.  Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. , 2007, Glycobiology.

[100]  N. Anderson,et al.  A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.

[101]  E. Go,et al.  GlycoPep DB: a tool for glycopeptide analysis using a "Smart Search". , 2007, Analytical chemistry.

[102]  Kit S. Lam,et al.  A Serum Glycomics Approach to Breast Cancer Biomarkers*S , 2007, Molecular & Cellular Proteomics.

[103]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  Mahesh Choolani,et al.  Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. , 2007, Neoplasia.

[105]  Richard S. Lee,et al.  Global methods for protein glycosylation analysis by mass spectrometry. , 2006, Biochimica et biophysica acta.

[106]  O. J. Semmes,et al.  Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers* , 2006, Molecular & Cellular Proteomics.

[107]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[108]  Osamu Ishikawa,et al.  Fucosylated haptoglobin is a novel marker for pancreatic cancer: A detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation , 2006, International journal of cancer.

[109]  Kit S Lam,et al.  Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. , 2006, Journal of proteome research.

[110]  Michelle A. Anderson,et al.  Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. , 2006, Journal of proteome research.

[111]  C. Huck,et al.  Biomarker discovery in breast cancer serum using 2‐D differential gel electrophoresis/ MALDI‐TOF/TOF and data validation by routine clinical assays , 2006, Electrophoresis.

[112]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[113]  André M Deelder,et al.  Protein glycosylation analysis by liquid chromatography-mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[114]  J. Carmody,et al.  Mass profiling‐directed isolation and identification of a stage‐specific serologic protein biomarker of advanced prostate cancer , 2005, Proteomics.

[115]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[116]  E. Diamandis,et al.  Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  Stephen Alexander,et al.  Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid , 2004, Clinical Cancer Research.

[118]  Zachary Shriver,et al.  Glycomics: a pathway to a class of new and improved therapeutics , 2004, Nature Reviews Drug Discovery.

[119]  T. Akahoshi,et al.  Analysis of the Oligosaccharide Chain of Human Serum Immunoglobulin G in Patients with Localized or Metastatic Cancer , 2004, Oncology.

[120]  Emanuel F Petricoin,et al.  Protein microarray detection strategies: focus on direct detection technologies. , 2004, Journal of immunological methods.

[121]  G. Rice,et al.  Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer , 2004, British Journal of Cancer.

[122]  R. Salgia,et al.  Haptoglobin α-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in Small cell lung cancer , 2004 .

[123]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[124]  M. Kostrzewa,et al.  Mass spectrometry-based clinical proteomics. , 2003, Pharmacogenomics.

[125]  J. Hirabayashi,et al.  Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins , 2003, Nature Biotechnology.

[126]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[127]  M. Mann,et al.  Proteomic analysis of post-translational modifications , 2003, Nature Biotechnology.

[128]  Andrew H. Thompson,et al.  Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. , 2003, Analytical chemistry.

[129]  M. Provencio,et al.  Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies , 2003, Annals of Surgical Oncology.

[130]  S. Nakahara,et al.  Prometastatic Effect ofN-Acetylglucosaminyltransferase V Is Due to Modification and Stabilization of Active Matriptase by Adding β1–6 GlcNAc Branching* , 2002, The Journal of Biological Chemistry.

[131]  G. Reid,et al.  Tandem mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions. , 2002, Analytical chemistry.

[132]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[133]  B. Yin,et al.  Molecular Cloning of the CA125 Ovarian Cancer Antigen , 2001, The Journal of Biological Chemistry.

[134]  M. Duffy,et al.  CA 15–3: A Prognostic Marker in Breast Cancer , 2000, The International journal of biological markers.

[135]  S. Hammarström.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. , 1999, Seminars in cancer biology.

[136]  Lin Chen,et al.  Transcriptional Regulation ofN-Acetylglucosaminyltransferase V by the srcOncogene* , 1997, The Journal of Biological Chemistry.

[137]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[138]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[139]  T R Fleming,et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. , 1993, JAMA.

[140]  Abraham Fuks,et al.  Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule , 1989, Cell.

[141]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[142]  S. Thompson,et al.  Elevated levels of abnormally-fucosylated haptoglobins in cancer sera. , 1987, British Journal of Cancer.

[143]  R. Kerbel,et al.  Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. , 1987, Science.